TABLE 1.
Serum no.a | DPIb | Inoculum | Results of indicated ELISA
|
|||
---|---|---|---|---|---|---|
E2c | ERNS
|
Peptide (OD)e | ||||
Ad | Bd | |||||
1 | 43 | CSFV Visbek/Han 95 | + | + | + | 0.171 |
2 | 16 | CSFV Visbek/Han 95 | + | + | + | 0.477 |
3 | 20 | CSFV Visbek/Han 95 | + | + | + | 1.796 |
4 | 20 | CSFV Visbek/Han 95 | + | − | + | 3.165 |
5 | 14 | CSFV Visbek/Han 95 | + | + | + | 0.7 |
6 | 21 | CSFV Alfort 187 | + | − | − | 0.186 |
7 | 29 | CSFV Diepholz1/Han94 | + | + | + | 2.25 |
8 | 29 | CSFV Diepholz1/Han94 | + | − | + | 2.619 |
9 | 29 | CSFV Diepholz1/Han94 | + | − | + | 1.857 |
10 | 34 | CSFV Visbek/Han95 | + | − | + | 3.87 |
11 | 55 | CSFV Visbek/Han95 | + | + | + | 1.122 |
12 | 93 | CSFV C-strain | + | + | + | 0.543 |
13 | 69 | CSFV Diepholz1/Han94 | + | + | + | 2.146 |
14 | 28 | CSFV Diepholz1/Han94 | − | + | + | 1.103 |
15 | BVDV NADL | − | − | − | 0.103 | |
16 | BDV | − | − | − | 0.45 | |
17 | BVDV 2214 | − | + | + | 0.161 | |
18 | BVDV NADL | − | − | − | 0.118 | |
19 | BVDV NADL + BDV | − | − | + | 0.136 | |
20 | BVDV + CSFV Alfort 187 | + | + | + | 3.208 | |
21 | BVDV Osloss | − | − | − | 0.146 | |
22 | BVDV Osloss | − | − | − | 0.151 | |
23 | BVDV Osloss | − | − | − | 0.151 | |
24 | BVDV Osloss | − | − | − | 0.162 | |
25 | BVDV Osloss | − | − | − | 0.172 | |
26 | BVDV Osloss | − | − | + | 0.164 | |
27 | BVDV Osloss | − | − | + | 0.149 | |
28 | BVDV Osloss | − | − | + | 0.163 | |
29 | BVDV Osloss | − | − | + | 0.215 | |
30 | CSFV Alfort 187 + BVDV Osloss | + | + | + | 0.567 |
Sera 21 to 29 were obtained from the same animal.
DPI, days postinfection.
Ceditest E2 ELISA (5).
Antibody-blocking ELISA based on complete Erns (see Materials and Methods).
OD values of >0.5 were considered positive results.